GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alkem Laboratories Ltd (NSE:ALKEM) » Definitions » Return-on-Tangible-Equity

Alkem Laboratories (NSE:ALKEM) Return-on-Tangible-Equity : 25.48% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Alkem Laboratories Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Alkem Laboratories's annualized net income for the quarter that ended in Dec. 2023 was ₹23,798 Mil. Alkem Laboratories's average shareholder tangible equity for the quarter that ended in Dec. 2023 was ₹93,411 Mil. Therefore, Alkem Laboratories's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 was 25.48%.

The historical rank and industry rank for Alkem Laboratories's Return-on-Tangible-Equity or its related term are showing as below:

NSE:ALKEM' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 11.78   Med: 19.83   Max: 25.61
Current: 17.78

During the past 13 years, Alkem Laboratories's highest Return-on-Tangible-Equity was 25.61%. The lowest was 11.78%. And the median was 19.83%.

NSE:ALKEM's Return-on-Tangible-Equity is ranked better than
78.36% of 938 companies
in the Drug Manufacturers industry
Industry Median: 6.335 vs NSE:ALKEM: 17.78

Alkem Laboratories Return-on-Tangible-Equity Historical Data

The historical data trend for Alkem Laboratories's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alkem Laboratories Return-on-Tangible-Equity Chart

Alkem Laboratories Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.06 21.32 25.61 21.97 11.78

Alkem Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.02 3.32 13.41 26.57 25.48

Competitive Comparison of Alkem Laboratories's Return-on-Tangible-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Alkem Laboratories's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alkem Laboratories's Return-on-Tangible-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alkem Laboratories's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Alkem Laboratories's Return-on-Tangible-Equity falls into.



Alkem Laboratories Return-on-Tangible-Equity Calculation

Alkem Laboratories's annualized Return-on-Tangible-Equity for the fiscal year that ended in Mar. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Mar. 2023 )  (A: Mar. 2022 )(A: Mar. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Mar. 2023 )  (A: Mar. 2022 )(A: Mar. 2023 )
=9841.7/( (81626.2+85527.4 )/ 2 )
=9841.7/83576.8
=11.78 %

Alkem Laboratories's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=23798.4/( (93410.8+0)/ 1 )
=23798.4/93410.8
=25.48 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Alkem Laboratories  (NSE:ALKEM) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Alkem Laboratories Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Alkem Laboratories's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Alkem Laboratories (NSE:ALKEM) Business Description

Traded in Other Exchanges
Address
Senapati Bapat Marg, Alkem House, Devashish Building, Lower Parel, Mumbai, MH, IND, 400 013
Alkem Laboratories Ltd is an Indian pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals in acute and chronic therapeutic areas, such as anti-infective, pain and analgesics, vitamins/minerals/nutrients, cardiac and Diabetology, Gynecology, neuro/central nervous system, dermatology, anti-diabetes, anti-osteoporosis, cardiovascular, and muscle relaxants, which are marketed in Indian and International markets. It operates through the pharmaceutical business segment.

Alkem Laboratories (NSE:ALKEM) Headlines

No Headlines